← Leaderboards
Laurence J.n. Cooper
City Of Hope/Beckman Research Institute
$14,619,391
Attributed
$17,216,526
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,816,526 · 13
FDA$400,000 · 1
By mechanism
R01$9,279,009 · 6
R44$2,677,080 · 2
P01$2,204,224 · 1
R21$1,460,886 · 3
R33$1,359,577 · 1
S10$235,750 · 1
Top collaborators
- Navin Varadarajan4 shared
- King C. Li3 shared
- Shahriar Yaghoubi3 shared
- Elizabeth J Shpall2 shared
- Rebecca L Berdeaux1 shared
Most similar at City Of Hope/Beckman Research Institute
Same institution · by research overlap
- Theodore G Krontiris$13,272,552
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteCellsSignal TransductionTumorIn VivoDesignAllogenicCd19 GeneMalignant NeoplasmsInfusion ProceduresAdoptive TransferClinical TrialsCell SurfaceCd28 GeneCd3 AntigensGenerationsResearch PersonnelTechnologyToxic EffectImmunotherapyBaseLeukemiaLeukemia/LymphomaRelapse
Grant awards (44)
Dynamic single-cell analysis instrument to evaluate immune cell function$462,781
R44 · FY2025 · GM · contact PI
Dynamic single-cell analysis instrument to evaluate immune cell function$56,415
R44 · FY2025 · GM · contact PI
Dynamic single-cell analysis instrument to evaluate immune cell function$1,483,544
R44 · FY2024 · GM · contact PI
Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing$350,000
R44 · FY2024 · TR
Dynamic single-cell analysis instrument to evaluate immune cell function$324,340
R44 · FY2023 · GM · contact PI
Quantitative single-cell biomarkers of T-cells to optimize tumor immunotherapy$455,093
R01 · FY2015 · CA
IMAGING T CELLS BY POSITRON EMISSION TOMOGRAPHY$564,591
R01 · FY2014 · CA · contact PI
Quantitative single-cell biomarkers of T-cells to optimize tumor immunotherapy$457,521
R01 · FY2014 · CA
T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia$308,475
R01 · FY2014 · CA · contact PI
Phase 1 Study of Umbilical Cord Blood-Derived T Cells in Malignant B Cells$200,000
R01 · FY2014 · FD · contact PI
IMAGING T CELLS BY POSITRON EMISSION TOMOGRAPHY$575,114
R01 · FY2013 · CA · contact PI
Quantitative single-cell biomarkers of T-cells to optimize tumor immunotherapy$446,107
R01 · FY2013 · CA
T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia$298,935
R01 · FY2013 · CA · contact PI
Phase 1 Study of Umbilical Cord Blood-Derived T Cells in Malignant B Cells$200,000
R01 · FY2013 · FD · contact PI
Quantitative single-cell biomarkers of T-cells to optimize tumor immunotherapy$729,130
R01 · FY2012 · CA
IMAGING T CELLS BY POSITRON EMISSION TOMOGRAPHY$627,610
R01 · FY2012 · CA · contact PI
T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia$318,015
R01 · FY2012 · CA · contact PI
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY$459,850
R33 · FY2011 · CA · contact PI
T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia$318,015
R01 · FY2011 · CA · contact PI
Enhancing the efficacy of CD19-specific cord blood-derived T Cells$283,822
R01 · FY2011 · CA · contact PI
Adoptive immunotherapy after umbilical cord blood transplant$283,822
R01 · FY2011 · CA · contact PI
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY$899,727
R33 · FY2010 · CA · contact PI
Targeting Post-Transplant Minimal Residual CD19+ ALL with Genetically-$524,715
P01 · FY2010 · CA · contact PI
T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia$303,780
R01 · FY2010 · CA · contact PI
Adoptive immunotherapy after umbilical cord blood transplant$292,600
R01 · FY2010 · CA · contact PI
Enhancing the efficacy of CD19-specific cord blood-derived T Cells$292,600
R01 · FY2010 · CA · contact PI
nCounter Prep Station and the Digital Analyzer$235,750
S10 · FY2010 · RR · contact PI
Adoptive immunotherapy after umbilical cord blood transplant$568,179
R01 · FY2009 · CA · contact PI
Targeting Post-Transplant Minimal Residual CD19+ ALL with Genetically-$476,519
P01 · FY2009 · CA · contact PI
Enhancing the efficacy of CD19-specific cord blood-derived T Cells$292,600
R01 · FY2009 · CA · contact PI
Adoptive immunotherapy after umbilical cord blood transplant$292,600
R01 · FY2009 · CA · contact PI
Targeting Post-Transplant Minimal Residual CD19+ ALL with Genetically-$456,968
P01 · FY2008 · CA · contact PI
Enhancing the efficacy of CD19-specific cord blood-derived T Cells$292,600
R01 · FY2008 · CA · contact PI
Adoptive immunotherapy after umbilical cord blood transplant$292,600
R01 · FY2008 · CA · contact PI
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY$168,750
R21 · FY2008 · CA · contact PI
Imaging Infused CD19 Specific T Cells in the Tumor$154,000
R21 · FY2008 · CA · contact PI
Targeting Post-Transplant Minimal Residual CD19+ ALL with Genetically-$453,508
P01 · FY2007 · CA · contact PI
Enhancing the efficacy of CD19-specific cord blood-derived T Cells$292,600
R01 · FY2007 · CA · contact PI
Adoptive immunotherapy after umbilical cord blood transplant$292,600
R01 · FY2007 · CA · contact PI
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY$202,499
R21 · FY2007 · CA · contact PI
Imaging Infused CD19 Specific T Cells in the Tumor$169,680
R21 · FY2007 · CA · contact PI
Targeting Post-Transplant Minimal Residual CD19+ ALL with Genetically-$292,514
P01 · FY2006 · CA · contact PI
CD19-Specific T-Cell Therapy for Follicular Lymphoma$382,700
R21 · FY2004 · CA
CD19-Specific T-Cell Therapy for Follicular Lymphoma$383,257
R21 · FY2003 · CA